Lumos Pharma Inc (LUMO)
2.18
-0.03
(-1.36%)
USD |
NASDAQ |
Jul 08, 16:00
2.18
0.00 (0.00%)
After-Hours: 18:53
Lumos Pharma SG&A Expense (Annual): 16.57M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 16.57M |
| December 31, 2022 | 15.71M |
| December 31, 2021 | 15.33M |
| December 31, 2020 | 17.26M |
| December 31, 2019 | 4.147M |
| December 31, 2018 | 29.22M |
| December 31, 2017 | 31.73M |
| December 31, 2016 | 33.23M |
| Date | Value |
|---|---|
| December 31, 2015 | 30.69M |
| December 31, 2014 | 19.33M |
| December 31, 2013 | 9.521M |
| December 31, 2012 | 7.108M |
| December 31, 2011 | 5.679M |
| December 31, 2010 | 6.074M |
| December 31, 2009 | 3.705M |
| December 31, 2008 | 4.597M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
4.147M
Minimum
2019
17.26M
Maximum
2020
13.80M
Average
15.71M
Median
2022
SG&A Expense (Annual) Benchmarks
| icad Inc | 17.06M |
| Perspective Therapeutics Inc | 21.06M |
| Palatin Technologies Inc | 15.29M |
| Bio-Path Holdings Inc | 4.235M |
| PDS Biotechnology Corp | 15.28M |